Cargando…

Low Drug Loading Hampers the Clinical Translation of Peptide Drugs-Containing Metered-Dose Inhalers

Peptide-based drugs have attracted extensive attention from the medical and pharmaceutical industry because of their relatively high safety and efficacy. However, most of the peptide drugs approved are administrated by injection, which can easily cause poor patient compliance. In this circumstance,...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Zhengwei, Shu, Lei, Huang, Ying, Wu, Chuanbin, Pan, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031202/
https://www.ncbi.nlm.nih.gov/pubmed/35455386
http://dx.doi.org/10.3390/ph15040389
_version_ 1784692332305580032
author Huang, Zhengwei
Shu, Lei
Huang, Ying
Wu, Chuanbin
Pan, Xin
author_facet Huang, Zhengwei
Shu, Lei
Huang, Ying
Wu, Chuanbin
Pan, Xin
author_sort Huang, Zhengwei
collection PubMed
description Peptide-based drugs have attracted extensive attention from the medical and pharmaceutical industry because of their relatively high safety and efficacy. However, most of the peptide drugs approved are administrated by injection, which can easily cause poor patient compliance. In this circumstance, pulmonary administration as an alternative to injection administration can not only avoid the above issue but also accelerate the absorption rate of peptide drugs and improve bioavailability. Among the pulmonary delivery systems available on the market, metered-dose inhalers (MDIs) have emerged as appealing candidates for pulmonary delivery systems with clinical translational value, owing to their many merits, including portable, easy-to-operate, and cost-effective properties. Nevertheless, the industrialization of peptide drugs-containing MDIs encounters a bottleneck of low drug loading, owing to the incompatibility between the propellant and the peptide drugs, which cannot be effectively overcome by the current carrier particle encapsulation strategy. Herein, we put forward the following strategies: (1) To screen amphiphilic materials with high surface activity and strong interaction with peptide drugs; (2) To construct a chemical connection between peptide drugs and amphiphilic substances; (3) To optimize the cosolvent for dispersing peptide drugs. We suppose these strategies have the potential to defeat the bottleneck problem and provide a new idea for the industrialization of peptide drugs-containing MDIs.
format Online
Article
Text
id pubmed-9031202
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90312022022-04-23 Low Drug Loading Hampers the Clinical Translation of Peptide Drugs-Containing Metered-Dose Inhalers Huang, Zhengwei Shu, Lei Huang, Ying Wu, Chuanbin Pan, Xin Pharmaceuticals (Basel) Perspective Peptide-based drugs have attracted extensive attention from the medical and pharmaceutical industry because of their relatively high safety and efficacy. However, most of the peptide drugs approved are administrated by injection, which can easily cause poor patient compliance. In this circumstance, pulmonary administration as an alternative to injection administration can not only avoid the above issue but also accelerate the absorption rate of peptide drugs and improve bioavailability. Among the pulmonary delivery systems available on the market, metered-dose inhalers (MDIs) have emerged as appealing candidates for pulmonary delivery systems with clinical translational value, owing to their many merits, including portable, easy-to-operate, and cost-effective properties. Nevertheless, the industrialization of peptide drugs-containing MDIs encounters a bottleneck of low drug loading, owing to the incompatibility between the propellant and the peptide drugs, which cannot be effectively overcome by the current carrier particle encapsulation strategy. Herein, we put forward the following strategies: (1) To screen amphiphilic materials with high surface activity and strong interaction with peptide drugs; (2) To construct a chemical connection between peptide drugs and amphiphilic substances; (3) To optimize the cosolvent for dispersing peptide drugs. We suppose these strategies have the potential to defeat the bottleneck problem and provide a new idea for the industrialization of peptide drugs-containing MDIs. MDPI 2022-03-23 /pmc/articles/PMC9031202/ /pubmed/35455386 http://dx.doi.org/10.3390/ph15040389 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Perspective
Huang, Zhengwei
Shu, Lei
Huang, Ying
Wu, Chuanbin
Pan, Xin
Low Drug Loading Hampers the Clinical Translation of Peptide Drugs-Containing Metered-Dose Inhalers
title Low Drug Loading Hampers the Clinical Translation of Peptide Drugs-Containing Metered-Dose Inhalers
title_full Low Drug Loading Hampers the Clinical Translation of Peptide Drugs-Containing Metered-Dose Inhalers
title_fullStr Low Drug Loading Hampers the Clinical Translation of Peptide Drugs-Containing Metered-Dose Inhalers
title_full_unstemmed Low Drug Loading Hampers the Clinical Translation of Peptide Drugs-Containing Metered-Dose Inhalers
title_short Low Drug Loading Hampers the Clinical Translation of Peptide Drugs-Containing Metered-Dose Inhalers
title_sort low drug loading hampers the clinical translation of peptide drugs-containing metered-dose inhalers
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031202/
https://www.ncbi.nlm.nih.gov/pubmed/35455386
http://dx.doi.org/10.3390/ph15040389
work_keys_str_mv AT huangzhengwei lowdrugloadinghamperstheclinicaltranslationofpeptidedrugscontainingmetereddoseinhalers
AT shulei lowdrugloadinghamperstheclinicaltranslationofpeptidedrugscontainingmetereddoseinhalers
AT huangying lowdrugloadinghamperstheclinicaltranslationofpeptidedrugscontainingmetereddoseinhalers
AT wuchuanbin lowdrugloadinghamperstheclinicaltranslationofpeptidedrugscontainingmetereddoseinhalers
AT panxin lowdrugloadinghamperstheclinicaltranslationofpeptidedrugscontainingmetereddoseinhalers